Hydromorphone

Last updated

Hydromorphone
Hydromorphone skeletal.svg
Hydromorphone molecule spacefill.png
Clinical data
Trade names Dilaudid, others
Other namesDihydromorphinone
AHFS/Drugs.com Monograph
MedlinePlus a682013
License data
Pregnancy
category
Dependence
liability 		High [2]
Addiction
liability 		High [3]
Routes of
administration 		By mouth, intramuscular, intravenous, subcutaneous
Drug class Opioid
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability By mouth: 25–50%, [5] Intranasal: 52–58%, [6] IV/IM: 100%
Protein binding 20%
Metabolism Liver
Onset of action 15–30 min [7]
Elimination half-life 2–3 hours [8]
Duration of action 4–5 hours [7]
Excretion Kidney
Identifiers
  • 4,5-α-Epoxy-3-hydroxy-17-methyl morphinan-6-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.006.713 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C17H19NO3
Molar mass 285.343 g·mol−1
3D model (JSmol)
Solubility in water HCl salt: 333
  • O=C4[C@@H]5Oc1c2c(ccc1O)C[C@H]3N(CC[C@]25[C@H]3CC4)C
  • InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1 Yes check.svgY
  • Key:WVLOADHCBXTIJK-YNHQPCIGSA-N Yes check.svgY
   (verify)

Hydromorphone, also known as dihydromorphinone, and sold under the brand name Dilaudid among others, is a morphinan opioid used to treat moderate to severe pain. [7] Typically, long-term use is only recommended for pain due to cancer. [9] It may be used by mouth or by injection into a vein, muscle, or under the skin. [7] Effects generally begin within half an hour and last for up to five hours. [7] A 2016 Cochrane review (updated in 2021) found little difference in benefit between hydromorphone and other opioids for cancer pain. [10]

Contents

Common side effects include dizziness, sleepiness, nausea, itchiness, and constipation. [7] Serious side effects may include abuse, low blood pressure, seizures, respiratory depression, and serotonin syndrome. [7] Rapidly decreasing the dose may result in opioid withdrawal. [7] Generally, use during pregnancy or breastfeeding is not recommended. [11] Hydromorphone is believed to work by activating opioid receptors, mainly in the brain and spinal cord. [7] Hydromorphone 2 mg IV is equivalent to approximately 10 mg morphine IV. [9]

Hydromorphone was patented in 1923. [12] Hydromorphone is made from morphine. [13] It is on the World Health Organization's List of Essential Medicines. [14] It is available as a generic medication. [7] In 2021, it was the 261st most commonly prescribed medication in the United States, with more than 1 million prescriptions. [15] [16]

Side effects

Adverse effects of hydromorphone are similar to those of other potent opioid analgesics such as morphine and heroin. The major hazards of hydromorphone include dose-related respiratory depression, urinary retention, bronchospasm, and sometimes, circulatory depression. [17] More common side effects include lightheadedness, dizziness, sedation, itching, constipation, nausea, vomiting, headache, perspiration, and hallucinations. [17] These symptoms are common in ambulatory patients and in those not experiencing severe pain.

Simultaneous use of hydromorphone with other opioids, muscle relaxants, tranquilizers, sedatives, and general anesthetics may cause a significant increase in respiratory depression, progressing to coma or death. Taking benzodiazepines (e.g., diazepam) in conjunction with hydromorphone may increase side effects such as dizziness and difficulty concentrating. [18] If simultaneous use of these drugs is required, dose adjustment may be made. [19]

A particular problem that may occur with hydromorphone is accidental administration in place of morphine due to a mix-up between the similar names, either at the time the prescription is written or when the drug is dispensed. This has led to several deaths and calls for hydromorphone to be distributed in distinctly different packaging from morphine to avoid confusion. [20] [21]

Massive overdoses are rarely observed in opioid-tolerant individuals, but when they occur, they may lead to circulatory system collapse. Symptoms of overdose include respiratory depression, drowsiness leading to coma and sometimes to death, drooping of skeletal muscles, low heart rate, and decreasing blood pressure. At the hospital, individuals with hydromorphone overdose are provided supportive care, such as assisted ventilation to provide oxygen and gut decontamination using activated charcoal through a nasogastric tube. Opioid antagonists, such as naloxone, also may be administered concurrently with oxygen supplementation. Naloxone works by reversing the effects of hydromorphone, and only is administered in the presence of significant respiratory depression and circulatory depression. [19]

Sugar cravings associated with hydromorphone use are the result of a glucose crash after transient hyperglycemia following injection, or a less profound lowering of blood sugar over a period of hours, in common with morphine, heroin, codeine, and other opioids.

Hormone imbalance

As with other opioids, hydromorphone (particularly during heavy chronic use) often causes temporary hypogonadism or hormone imbalance. [22]

Neurotoxicity

In the setting of prolonged use, high dosage, and/or kidney dysfunction, hydromorphone has been associated with neuroexcitatory symptoms such as tremor, myoclonus, agitation, and cognitive dysfunction. [23] [24] [25] This toxicity is less than that associated with other classes of opioids such as the pethidine class of synthetics in particular.

Withdrawal

Users of hydromorphone may experience painful symptoms if the drug is suspended. [26] Some people cannot tolerate the symptoms, which results in continuous drug use. [26] Symptoms of opioid withdrawal are not easy to decipher, as there are differences between drug-seeking behaviors and true withdrawal effects. [27] Symptoms associated with hydromorphone withdrawal include: [26] [27] [28]

In the clinical setting, excessive secretion of tears, yawning, and dilation of pupils are helpful presentations in diagnosing opioid withdrawal. [29] Hydromorphone is a rapid-acting painkiller; however, some formulations may last up to several hours. Patients who stop taking this drug abruptly may experience withdrawal symptoms, [28] [30] which may start within hours of taking the last dose of hydromorphone, and last up to several weeks. [26] Withdrawal symptoms in people who stopped taking the opioid may be managed by using opioids or non-opioid adjuncts. [31] Methadone is an opioid commonly used for this kind of therapy. However, the selection of therapy should be tailored to each specific person. [32] Methadone also is used for detoxification in people who have opiate addiction, such as heroin or drugs similar to morphine. [32] It may be given orally or intramuscularly. There is controversy regarding whether any opioid (such as methadone) should be included in the treatment of opioid withdrawal symptoms, since these agents also may cause relapse when therapy is suspended. [26] Clonidine is a non-opioid adjunct which may be used in situations where opioid use is not desired, such as in patients with high blood pressure. [33]

Interactions

CNS depressants may enhance the depressant effects of hydromorphone, such as other opioids, anesthetics, sedatives, hypnotics, barbiturates, benzodiazepines, phenothiazines, chloral hydrate, dimenhydrinate, and glutethimide. The depressant effect of hydromorphone also may be enhanced by monoamine oxidase inhibitors (MAO inhibitors), first-generation antihistamines (e.g., brompheniramine, promethazine, diphenhydramine, chlorphenamine), beta blockers, and alcohol. When combined therapy is contemplated, the dose of one or both agents should be reduced. [23]

Pharmacology

Hydromorphone at opioid receptors [34]
Affinities (Ki Tooltip Inhibitor constant)Ratio
MOR Tooltip μ-Opioid receptor DOR Tooltip δ-Opioid receptor KOR Tooltip κ-Opioid receptorMOR:DOR:KOR
0.47 nM18.5 nM24.9 nM1:39:53

Equianalgesic doses [35] [36] [37]
Compound Route Dose
Codeine PO200 mg
Hydrocodone PO20–30 mg
HydromorphonePO7.5 mg
HydromorphoneIV1.5 mg
Morphine PO30 mg
Morphine IV10 mg
Oxycodone PO20 mg
Oxycodone IV10 mg
Oxymorphone PO10 mg
Oxymorphone IV1 mg

Hydromorphone is a semi-synthetic μ-opioid agonist. As a hydrogenated ketone of morphine, it shares the pharmacologic properties typical of opioid analgesics. Hydromorphone and related opioids produce their major effects on the central nervous system and gastrointestinal tract. These include analgesia, drowsiness, mental clouding, changes in mood, euphoria or dysphoria, respiratory depression, cough suppression, decreased gastrointestinal motility, nausea, vomiting, increased cerebrospinal fluid pressure, increased biliary pressure, and increased pinpoint constriction of the pupils. [30]

Formulations

Hydromorphone.JPG

Hydromorphone is available in parenteral, rectal, subcutaneous, and oral formulations, and also can be administered via epidural or intrathecal injection. [38] Hydromorphone also has been administered via nebulization to treat shortness of breath, but it is not used as a route for pain control due to low bioavailability. [39] Transdermal delivery systems are also under consideration to induce local skin analgesia. [40]

Concentrated aqueous solutions of hydromorphone hydrochloride have a visibly different refractive index from pure water, isotonic 9‰ (0·9 per cent) saline and the like, especially when stored in clear ampoules and phials may acquire a slight clear amber discolouration upon exposure to light; this reportedly has no effect on the potency of the solution, but 14-dihydromorphinones such as hydromorphone, oxymorphone, and relatives come with instructions to protect from light. [41] Ampoules of solution which have developed a precipitate should be discarded. [41]

Battery-powered intrathecal drug delivery systems are implanted for chronic pain when other options are ruled out, such as surgery and traditional pharmacotherapy, provided that the patient is considered a suitable fit in terms of any contraindications, both physiological and psychological. [42]

An extended-release (once-daily) version of hydromorphone is available in the United States. [43] Previously, an extended-release version of hydromorphone, Palladone, was available before being voluntarily withdrawn from the market after a July 2005 FDA advisory warned of a high overdose potential when taken with alcohol. As of March 2010, it is still available in the United Kingdom under the brand name Palladone SR, Nepal under the brand name Opidol, and in most other European countries, [44] In Canada, pre­scrip­tion continuous release hydro­morphone is available as both brand name (Hydro­morph Contin) and generic formu­lations (Apo-Hydro­morphone CR). [45]

Pharmacokinetics

The chemical modification of the morphine molecule to hydromorphone results in higher lipid solubility and greater ability to cross the blood–brain barrier to produce more rapid and complete central nervous system penetration. On a per milligram basis, hydromorphone is considered to be five times as potent as morphine; although the conversion ratio may vary from 4–8 times, five times is in typical clinical usage. [46] [47] The development of tolerance also may vary among individuals.

Patients with renal abnormalities must exercise caution when dosing hydromorphone. In those with renal impairment, the half-life of hydromorphone may increase to as much as 40 hours. The typical half-life of intravenous hydromorphone is 2.3 hours. [48] Peak plasma levels usually occur between 30 and 60 minutes after oral dosing. [49]

The onset of action for hydromorphone administered intravenously is less than 5 minutes and within 30 minutes of oral administration (immediate release). [39]

Metabolism

While other opioids in its class, such as codeine or oxycodone, are metabolized via CYP450 enzymes, hydromorphone is not. [50] Hydromorphone is extensively metabolized in the liver to hydromorphone-3-glucuronide, which has no analgesic effects. As similarly seen with the morphine metabolite, morphine-3-glucuronide, a build-up in levels of hydromorphone-3-glucuronide may produce excitatory neurotoxic effects such as restlessness, myoclonus and hyperalgesia. Patients with compromised kidney function and older patients are at higher risk for metabolite accumulation. [51]

Chemistry

With a formula of C17H19NO3 and a molecular weight of 285.343, both identical to morphine, hydromorphone can be considered a structural isomer of morphine and is a hydrogenated ketone thereof. [52]

Hydromorphone is made from morphine either by direct re-arrangement (made by reflux heating of alcoholic or acidic aqueous solution of morphine in the presence of platinum or palladium catalyst) or reduction to dihydromorphine (usually via catalytic hydrogenation), followed by oxidation with benzophenone in presence of potassium tert butoxide or aluminium tert butoxide (Oppenauer oxidation). The 6 ketone group may be replaced with a methylene group via the Wittig reaction to produce 6-Methylenedihydrodesoxymorphine, which is 80× stronger than morphine. [53]

Changing morphine into hydromorphone increases its activity and, therefore, makes hydromorphone approximately eight times stronger than morphine on a weight basis, all other things being equal.[ citation needed ] Changed also is lipid solubility, contributing to hydromorphone's having a more rapid onset of action and alterations to the overall absorption, distribution, metabolism, and elimination profile as well as the side effect profile (in general, less nausea and itching) versus that of morphine. The semi-synthetic opiates, of which hydromorphone and its codeine analogue hydrocodone are among the best-known and oldest, include a huge number of drugs of varying strengths and with differences among themselves both subtle and stark, allowing for many different options for treatment.

Hydromorphone is more soluble in water than morphine; therefore, hydromorphone solutions may be produced to deliver the drug in a smaller volume of water. The hydrochloride salt is soluble in three parts of water, whereas a gram of morphine hydrochloride dissolves in 16 ml of water; for all common purposes, the pure powder for hospital use can be used to produce solutions of virtually arbitrary concentration. When the powder appeared on the street, this very small volume of powder needed for a dose means that overdoses are likely for those who mistake it for heroin or other powdered narcotics, especially those that have been diluted prior to consumption. [54]

Endogenous production

Hydromorphone is made from morphine via catalytic hydrogenation and also is produced in trace amounts by human and other mammalian metabolisms of morphine. It occasionally appears in assays of opium latex in very small quantities, apparently forming in the plant in an unknown percentage of cases under poorly understood conditions.[ citation needed ]

Bacteria

Some bacteria have been shown to be able to turn morphine into closely related drugs, including hydromorphone and dihydromorphine among others. The bacterium Pseudomonas putida serotype M10 produces a naturally-occurring NADH-dependent morphinone reductase that can work on unsaturated 7,8 bonds, with result that, when these bacteria are living in an aqueous solution containing morphine, significant amounts of hydromorphone form, as it is an intermediary metabolite in this process; the same goes for codeine being turned into hydrocodone. [55]

The process gave rise to various concentrations of hydromorphone, dihydromorphine, hydromorphinol, and oxymorphone during the experiments. Three paths were found: from morphine to hydromorphone with dihydromorphine as the penultimate step, from morphine to hydromorphone with morphinone as the penultimate step, and from morphine to hydromorphinol to hydromorphone.

History

Hydromorphone was patented in 1923. [12] It was introduced to the mass market in 1926 under the brand name Dilaudid, [56] indicating its derivation and degree of similarity to morphine (by way of laudanum).

Society and culture

Names

Hydromorphone is known in various countries around the world by the brand names Hydal, Dimorphone, Exalgo, Sophidone LP, Dilaudid, Hydrostat, Hydromorfan, Hydromorphan, Hymorphan, Laudicon, Opidol, Palladone, Hydromorph Contin, and others. An extended-release version of hydromorphone, called Palladone, was available for a short time in the United States before being voluntarily withdrawn from the market after a July 2005 FDA advisory warned of a high overdose potential when taken with alcohol. [57] As of March 2010, it is still available in Nepal under the brand name Opidol, in the United Kingdom under the brand name Palladone SR, and in most other European countries.

There has also been a once-daily prolonged release version of hydromorphone available in Australia under the brand name Jurnista as of May 2009. [58]

In the United States, the main drug control agency, the Drug Enforcement Administration, reports an increase in annual aggregate production quotas of hydromorphone from 766 kilograms (1,689 pounds) in 1998 to 3,300 kilograms (7,300 lb) in 2006, and an increase in prescriptions in this time of 289%, from about 470,000 to 1,830,000. The 2013 production quota was 5,968 kilograms (13,157 lb). [59]

Like all opioids used for analgesia, hydromorphone is potentially habit-forming and is listed in Schedule II of the United States Controlled Substances Act of 1970 as well as in similar levels under the drugs laws of practically all other countries and it is listed in the Single Convention On Narcotic Drugs. The DEA ACSCN for hydromorphone is 9150.

Hydromorphone is listed under the German Betäubungsmittelgesetz as a Betäubungsmittel in the most restricted schedule for medicinal drugs; it is controlled similarly in Austria (Suchtgift) under the SMG and the Swiss BetmG. The Misuse of Drugs Act 1971 (United Kingdom) and comparable French, Canadian, Australian, Italian, Czech, Croatian, Slovenian, Swedish, Polish, Spanish, Greek, Russian, and other laws similarly control it, as do regulations in virtually all other countries.

Use in executions

In 2009, Ohio approved the use of an intramuscular injection of 500 mg of hydromorphone and a supratherapeutic dose of midazolam as a backup means of carrying out executions by lethal injection when a suitable vein cannot be found for intravenous injection. [60]

Hydromorphone and midazolam was injected intravenously to execute double-murderer Joseph Wood in Arizona on 24 July 2014. Wood was heavily sedated ( surgical anesthesia ) within four minutes from start, but took almost two hours to transition to stage 4 (cessation of respiration) and death. [61]

Related Research Articles

<span class="mw-page-title-main">Hydrocodone</span> Opioid drug used in pain relief

Hydrocodone, also known as dihydrocodeinone, is a semi-synthetic opioid used to treat pain and as a cough suppressant. It is taken by mouth. Typically, it is dispensed as the combination acetaminophen/hydrocodone or ibuprofen/hydrocodone for pain severe enough to require an opioid and in combination with homatropine methylbromide to relieve cough. It is also available by itself in a long-acting form sold under the brand name Zohydro ER, among others, to treat severe pain of a prolonged duration. Hydrocodone is a controlled drug: in the United States, it is classified as a Schedule II Controlled Substance.

<span class="mw-page-title-main">Morphine</span> Pain medication of the opiate family

Morphine, formerly also called morphia, is an opiate that is found naturally in opium, a dark brown resin produced by drying the latex of opium poppies. It is mainly used as an analgesic. There are numerous methods used to administer morphine: oral; sublingual; via inhalation; injection into a muscle, injection under the skin, or injection into the spinal cord area; transdermal; or via rectal suppository. It acts directly on the central nervous system (CNS) to induce analgesia and alter perception and emotional response to pain. Physical and psychological dependence and tolerance may develop with repeated administration. It can be taken for both acute pain and chronic pain and is frequently used for pain from myocardial infarction, kidney stones, and during labor. Its maximum effect is reached after about 20 minutes when administered intravenously and 60 minutes when administered by mouth, while the duration of its effect is 3–7 hours. Long-acting formulations of morphine are sold under the brand names MS Contin and Kadian, among others. Generic long-acting formulations are also available.

<span class="mw-page-title-main">Methadone</span> Opioid medication

Methadone, sold under the brand names Dolophine and Methadose among others, is a synthetic opioid used medically to treat chronic pain and opioid use disorder. Prescribed for daily use, the medicine relieves cravings and opioid withdrawal symptoms. Withdrawal management using methadone can be accomplished in less than a month, or it may be done gradually over a longer period of time, or simply maintained for the rest of the patient's life. While a single dose has a rapid effect, maximum effect can take up to five days of use. After long-term use, in people with normal liver function, effects last 8 to 36 hours. Methadone is usually taken by mouth and rarely by injection into a muscle or vein.

<span class="mw-page-title-main">Oxycodone</span> Opioid medication

Oxycodone, sold under the brand name Roxicodone and OxyContin among others, is a semi-synthetic opioid used medically for treatment of moderate to severe pain. It is highly addictive and is a commonly abused drug. It is usually taken by mouth, and is available in immediate-release and controlled-release formulations. Onset of pain relief typically begins within fifteen minutes and lasts for up to six hours with the immediate-release formulation. In the United Kingdom, it is available by injection. Combination products are also available with paracetamol (acetaminophen), ibuprofen, naloxone, naltrexone, and aspirin.

<span class="mw-page-title-main">Naloxone</span> Opioid receptor antagonist

Naloxone is an opioid antagonist: a medication used to reverse or reduce the effects of opioids. For example, it is used to restore breathing after an opioid overdose. It is also known as Narcan. Effects begin within two minutes when given intravenously, five minutes when injected into a muscle, and ten minutes as a nasal spray. Naloxone blocks the effects of opioids for 30 to 90 minutes.

<span class="mw-page-title-main">Opioid</span> Psychoactive chemical

Opioids are a class of drugs that derive from, or mimic, natural substances found in the opium poppy plant. Opioids work in the brain to produce a variety of effects, including pain relief. As a class of substances, they act on opioid receptors to produce morphine-like effects.

<span class="mw-page-title-main">Pethidine</span> Opioid analgesic

Pethidine, also known as meperidine and sold under the brand name Demerol among others, is a fully synthetic opioid pain medication of the phenylpiperidine class. Synthesized in 1938 as a potential anticholinergic agent by the German chemist Otto Eisleb, its analgesic properties were first recognized by Otto Schaumann while working for IG Farben, in Germany. Pethidine is the prototype of a large family of analgesics including the pethidine 4-phenylpiperidines, the prodines, bemidones, and others more distant, including diphenoxylate and analogues.

<span class="mw-page-title-main">Buprenorphine</span> Opioid used to treat pain & opioid use disorder

Buprenorphine, sold under the brand name Subutex among others, is an opioid used to treat opioid use disorder, acute pain, and chronic pain. It can be used under the tongue (sublingual), in the cheek (buccal), by injection, as a skin patch (transdermal), or as an implant. For opioid use disorder, the patient must have moderate opioid withdrawal symptoms before buprenorphine can be administered under direct observation of a health-care provider.

<span class="mw-page-title-main">Oxymorphone</span> Opioid analgesic drug

Oxymorphone is a highly potent opioid analgesic indicated for treatment of severe pain. Pain relief after injection begins after about 5–10 minutes, after oral administration it begins after about 30 minutes, and lasts about 3–4 hours for immediate-release tablets and 12 hours for extended-release tablets. The elimination half-life of oxymorphone is much faster intravenously, and as such, the drug is most commonly used orally. Like oxycodone, which metabolizes to oxymorphone, oxymorphone has a high potential to be abused.

<span class="mw-page-title-main">Dihydrocodeine</span> Opioid

Dihydrocodeine is a semi-synthetic opioid analgesic prescribed for pain or severe dyspnea, or as an antitussive, either alone or compounded with paracetamol (acetaminophen) or aspirin. It was developed in Germany in 1908 and first marketed in 1911.

<span class="mw-page-title-main">Sufentanil</span> Synthetic opioid analgesic drug

Sufentanil, sold under the brand names Sufenta among others, is a synthetic opioid analgesic drug approximately 5 to 10 times as potent as its parent drug, fentanyl, and 500 to 1,000 times as potent as morphine. Structurally, sufentanil differs from fentanyl through the addition of a methoxymethyl group on the piperidine ring, and the replacement of the phenyl ring by thiophene. Sufentanil first was synthesized at Janssen Pharmaceutica in 1974.

<span class="mw-page-title-main">Remifentanil</span> Synthetic opioid analgesic

Remifentanil, marketed under the brand name Ultiva is a potent, short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high-dose opioid and low-dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.

<span class="mw-page-title-main">Nalbuphine</span> Opioid analgesic

Nalbuphine, sold under the brand names Nubain among others, is an opioid analgesic which is used in the treatment of pain. It is given by injection into a vein, muscle, or fat.

<span class="mw-page-title-main">Dihydromorphine</span> Semi-synthetic opioid analgesic drug

Dihydromorphine is a semi-synthetic opioid structurally related to and derived from morphine. The 7,8-double bond in morphine is reduced to a single bond to get dihydromorphine. Dihydromorphine is a moderately strong analgesic and is used clinically in the treatment of pain and also is an active metabolite of the analgesic opioid drug dihydrocodeine. Dihydromorphine occurs in trace quantities in assays of opium on occasion, as does dihydrocodeine, dihydrothebaine, tetrahydrothebaine, etc. The process for manufacturing dihydromorphine from morphine for pharmaceutical use was developed in Germany in the late 19th century, with the synthesis being published in 1900 and the drug introduced clinically as Paramorfan shortly thereafter. A high-yield synthesis from tetrahydrothebaine was later developed.

<span class="mw-page-title-main">Diacetyldihydromorphine</span> Opioid analgesic drug

Diacetyldihydromorphine is a potent opiate derivative developed in Germany in 1928 which is rarely used in some countries for the treatment of severe pain such as that caused by terminal cancer, as another form of diacetylmorphine. Diacetyldihydromorphine is fast-acting and longer-lasting than diamorphine, with a duration of action of around 4–7 hours.

<span class="mw-page-title-main">Codeine</span> Opiate and prodrug of morphine used to treat pain

Codeine is an opiate and prodrug of morphine mainly used to treat pain, coughing, and diarrhea. It is also commonly used as a recreational drug. It is found naturally in the sap of the opium poppy, Papaver somniferum. It is typically used to treat mild to moderate degrees of pain. Greater benefit may occur when combined with paracetamol (acetaminophen) or a nonsteroidal anti-inflammatory drug (NSAID) such as aspirin or ibuprofen. Evidence does not support its use for acute cough suppression in children. In Europe, it is not recommended as a cough medicine in those under 12 years of age. It is generally taken by mouth. It typically starts working after half an hour, with maximum effect at two hours. Its effects last for about four to six hours. Codeine exhibits abuse potential similar to other opioid medications, including a risk of addiction and overdose.

<span class="mw-page-title-main">Tapentadol</span> Opioid analgesic of benzenoid class

Tapentadol, sold under the brand name Nucynta among others, is an opioid analgesic of the benzenoid class with a dual mode of action as an agonist of the μ-opioid receptor and as a norepinephrine reuptake inhibitor (NRI). Analgesia occurs within 32 minutes of oral administration, and lasts for 4–6 hours.

<span class="mw-page-title-main">Dezocine</span> Opioid analgesic

Dezocine, sold under the brand name Dalgan, is an atypical opioid analgesic which is used in the treatment of pain. It is used by intravenous infusion and intramuscular injection.

An equianalgesic chart is a conversion chart that lists equivalent doses of analgesics. Equianalgesic charts are used for calculation of an equivalent dose between different analgesics. Tables of this general type are also available for NSAIDs, benzodiazepines, depressants, stimulants, anticholinergics and others.

<span class="mw-page-title-main">Opiate</span> Substance derived from opium

An opiate is an alkaloid substance derived from opium. It differs from the similar term opioid in that the latter is used to designate all substances, both natural and synthetic, that bind to opioid receptors in the brain. Opiates are alkaloid compounds naturally found in the opium poppy plant Papaver somniferum. The psychoactive compounds found in the opium plant include morphine, codeine, and thebaine. Opiates have long been used for a variety of medical conditions, with evidence of opiate trade and use for pain relief as early as the eighth century AD. Most opiates are considered drugs with moderate to high abuse potential and are listed on various "Substance-Control Schedules" under the Uniform Controlled Substances Act of the United States of America.

References

  1. ↑ "Hydromorphone Use During Pregnancy". Drugs.com. 19 November 2019. Retrieved 16 May 2020.
  2. ↑ Bonewit-West K, Hunt SA, Applegate E (2012). Today's Medical Assistant: Clinical and Administrative Procedures. Elsevier Health Sciences. p. 571. ISBN   9781455701506.
  3. ↑ Bonewit-West K, Hunt SA, Applegate E (2012). Today's Medical Assistant: Clinical and Administrative Procedures. Elsevier Health Sciences. p. 571. ISBN   9781455701506. Archived from the original on 10 January 2023. Retrieved 20 August 2019.
  4. ↑ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  5. ↑ Polsten GR, Wallace MS (21 June 2016). "Analgesic Agents in Rheumatic Disease". In Firestein GS, Budd R, Gabriel SE, McInnes IB, O'Dell JR (eds.). Kelley and Firestein's Textbook of Rheumatology. Elsevier Health Sciences. pp. 1081–. ISBN   978-0-323-41494-4.
  6. ↑ Coda BA, Rudy AC, Archer SM, Wermeling DP (July 2003). "Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers". Anesthesia and Analgesia. 97 (1): 117–23, table of contents. CiteSeerX   10.1.1.551.6509 . doi:10.1213/01.ANE.0000066311.40978.4F. PMID   12818953. S2CID   22694749.
  7. 1 2 3 4 5 6 7 8 9 10 "Hydromorphone Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 15 April 2019.
  8. ↑ Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL (April 1981). "Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects". Journal of Clinical Pharmacology. 21 (4): 152–156. doi:10.1002/j.1552-4604.1981.tb05693.x. PMID   6165742. S2CID   29864565.
  9. 1 2 British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 24, 456. ISBN   9780857113382.
  10. ↑ Li Y, Ma J, Lu G, Dou Z, Knaggs R, Xia J, et al. (August 2021). "Hydromorphone for cancer pain". The Cochrane Database of Systematic Reviews. 2021 (8): CD011108. doi:10.1002/14651858.CD011108.pub3. PMC   8406835 . PMID   34350974.
  11. ↑ "Hydromorphone Use During Pregnancy". Drugs.com. Retrieved 15 April 2019.
  12. 1 2 Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 526. ISBN   9783527607495.
  13. ↑ Vardanyan R, Hruby V (2006). Synthesis of Essential Drugs. Elsevier. p. 25. ISBN   9780080462127.
  14. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl: 10665/371090 . WHO/MHP/HPS/EML/2023.02.
  15. ↑ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  16. ↑ "Hydromorphone - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
  17. 1 2 "Hydromorphone Monograph (Side Effects & Drug Interactions)". RxList Inc. 2008. Archived from the original on 13 February 2008.
  18. ↑ "Drug interactions between Dilaudid and Valium" . Retrieved 19 November 2014.
  19. 1 2 "Dilaudid (hydromorphone hydrochloride) Oral LiquidDilaudid (hydromorphone hydrochloride) Tablets". app.purduepharma.com. Archived from the original on 4 March 2016. Retrieved 5 November 2015.
  20. ↑ Cohen MR (June 1992). "Doctor was thinking of the wrong drug". Nursing. 22 (6): 25. doi:10.1097/00152193-199206000-00009. PMID   1377371.
  21. ↑ Tuohy N, Paparella S (December 2005). "Look-alike and sound-alike drugs: errors just waiting to happen". Journal of Emergency Nursing. 31 (6): 569–571. doi:10.1016/j.jen.2005.07.012. PMID   16308048.
  22. ↑ Brennan MJ (March 2013). "The effect of opioid therapy on endocrine function". The American Journal of Medicine. 126 (3 Suppl 1): S12–S18. doi:10.1016/j.amjmed.2012.12.001. PMID   23414717.
  23. 1 2 Thwaites D, McCann S, Broderick P (August 2004). "Hydromorphone neuroexcitation". Journal of Palliative Medicine. 7 (4): 545–550. doi:10.1089/1096621041838362. PMID   15353098.
  24. ↑ Gagnon DJ, Jwo K (2013). "Tremors and agitation following low-dose intravenous hydromorphone administration in a patient with kidney dysfunction". The Annals of Pharmacotherapy. 47 (7–8): e34. doi:10.1345/aph.1R784. PMID   23715067. S2CID   21782204.
  25. ↑ Rapp SE, Egan KJ, Ross BK, Wild LM, Terman GW, Ching JM (May 1996). "A multidimensional comparison of morphine and hydromorphone patient-controlled analgesia". Anesthesia and Analgesia. 82 (5): 1043–1048. doi: 10.1213/00000539-199605000-00029 . PMID   8610865.
  26. 1 2 3 4 5 "Hydromorphone / Dilaudid Detox". Rapid Drug Detox. Retrieved 5 November 2015.
  27. 1 2 "Dilaudid Abuse & Addiction Withdrawals, Signs, Symptoms & Effects – Acadiana Addiction Center". www.acadianaaddiction.com. Retrieved 5 November 2015.
  28. 1 2 "Hydromorphone Drug Information". Narconon International. Retrieved 5 November 2015.
  29. ↑ McKeown NJ, West PL (13 July 2022). VanDeVoort JT, Burns MJ, Gaeta TJ (eds.). "Withdrawal Syndromes: Practice Essentials, Background, Pathophysiology". Medscape.
  30. 1 2 "DILAUDID® ORAL LIQUID and DILAUDID® TABLETS Package Insert" (PDF). FDA. 2007. Retrieved 5 November 2015.
  31. ↑ "Opioid withdrawal protocol" (PDF). www.saskatoonhealthregion.ca. Archived from the original (PDF) on 25 November 2015. Retrieved 5 November 2015.
  32. 1 2 "4 Treatment Protocols". Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series. Vol. 40. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). 1 January 2004.
  33. ↑ Bell CC (January 1983). "Simultaneous treatment of hypertension and opiate withdrawal using an alpha 2-adrenergic agonist". Journal of the National Medical Association. 75 (1): 89–93. PMC   2561435 . PMID   6131140.
  34. ↑ Filizola M, Villar HO, Loew GH (January 2001). "Molecular determinants of non-specific recognition of delta, mu, and kappa opioid receptors". Bioorganic & Medicinal Chemistry. 9 (1): 69–76. doi:10.1016/S0968-0896(00)00223-6. PMID   11197347.
  35. ↑ King TL, Brucker MC (25 October 2010). Pharmacology for Women's Health. Jones & Bartlett Publishers. pp. 332–. ISBN   978-1-4496-1073-9.
  36. ↑ Chestnut DH, Wong CA, Tsen LC, Kee WD, Beilin Y, Mhyre J (28 February 2014). Chestnut's Obstetric Anesthesia: Principles and Practice E-Book. Elsevier Health Sciences. pp. 611–. ISBN   978-0-323-11374-8.
  37. ↑ Tiziani AP (1 June 2013). Havard's Nursing Guide to Drugs. Elsevier Health Sciences. pp. 933–. ISBN   978-0-7295-8162-2.
  38. ↑ Nersesyan H, Slavin KV (June 2007). "Current approach to cancer pain management: Availability and implications of different treatment options". Therapeutics and Clinical Risk Management. 3 (3): 381–400. PMC   2386360 . PMID   18488078.
  39. 1 2 Sarhill N, Walsh D, Nelson KA (March 2001). "Hydromorphone: pharmacology and clinical applications in cancer patients". Supportive Care in Cancer. 9 (2): 84–96. doi:10.1007/s005200000183. PMID   11305075. S2CID   22849970.
  40. ↑ Smith A, Gomez-Panzani E, Mills S, Rainey G, Tolia G, Tagliaferri F, et al. (2006). "(807) 24-hour transdermal delivery of hydromorphone hydrochloride". The Journal of Pain (Clinical trial abstract). 7 (4): S52. doi: 10.1016/j.jpain.2006.01.209 . ISSN   1526-5900.
  41. 1 2 Dilaudid HP package insert Nov 2004
  42. ↑ Knight KH, Brand FM, Mchaourab AS, Veneziano G (February 2007). "Implantable intrathecal pumps for chronic pain: highlights and updates". Croatian Medical Journal. 48 (1): 22–34. PMC   2080496 . PMID   17309136.
  43. ↑ "EXALGO (hydromorphone hydrochloride) extended release tablets Package Insert" (PDF). FDA. 2010. Retrieved 5 November 2015.
  44. ↑ "zalicus.com". www.zalicus.com. Retrieved 2 September 2017.
  45. ↑ "Summary Safety Review - HYDROmorph Contin and generic hydromorphone controlled release capsules. - Health Canada". Government of Canada: Drugs, health & consumer products. 10 September 2020. Retrieved 22 September 2024.
  46. ↑ "Opioid Conversion Guidelines" (PDF). alfredhealth.org.au. Archived from the original (PDF) on 4 March 2016. Retrieved 2 September 2017.
  47. ↑ "Switching Opioids" (PDF). mcmaster.ca. Retrieved 2 September 2017.
  48. ↑ "Hydromorphone". That's Poppycock!. 19 February 2009. Archived from the original on 14 October 2012. Retrieved 5 November 2012.
  49. ↑ "Dilaudid Clinical Pharmacology". rxlist.com. Archived from the original on 12 June 2008. Retrieved 2 September 2017.
  50. ↑ Gregory TB (December 2013). "Hydromorphone: evolving to meet the challenges of today's health care environment". Clinical Therapeutics. 35 (12): 2007–2027. doi:10.1016/j.clinthera.2013.09.027. PMID   24290733.
  51. ↑ Buck M (July 2008). "Use of Hydromorphone in Children and Adolescents" (PDF). University of Virginia Children's Hospital. Archived from the original (PDF) on 17 February 2014. Retrieved 5 November 2015.
  52. ↑ Merck Index 2003, "Morphine" and "Hydromorphone"
  53. ↑ PHA 4220 – Neurology Pharmacotherapeutics Archived 16 July 2007 at the Wayback Machine
  54. ↑ "Hydromorphone Hydrochloride" (PDF). Stamford, CT: Purdue Pharma L.P. 13 October 2009. MSDS No. 71681. Archived from the original (PDF) on 17 January 2015. Retrieved 5 November 2015.
  55. ↑ Long MT, Hailes AM, Kirby GW, Bruce NC (October 1995). "Transformations of morphine alkaloids by Pseudomonas putida M10". Applied and Environmental Microbiology. 61 (10): 3645–3649. Bibcode:1995ApEnM..61.3645L. doi:10.1128/AEM.61.10.3645-3649.1995. PMC   167664 . PMID   7487001.
  56. ↑ Felden L, Walter C, Harder S, Treede RD, Kayser H, Drover D, et al. (September 2011). "Comparative clinical effects of hydromorphone and morphine: a meta-analysis". British Journal of Anaesthesia. 107 (3): 319–328. doi: 10.1093/bja/aer232 . PMID   21841049.
  57. ↑ "Information for Healthcare Professionals: Hydromorphone Hydrochloride Extended-Release Capsules (marketed as Palladone)". Center for Drug Evaluation and Research. 15 July 2005. Retrieved 16 August 2016.
  58. ↑ "Hydromorphone prolonged-release tablets (Jurnista) for chronic severe disabling pain". NPS Medicinewise. May 2009. Retrieved 7 December 2020.
  59. ↑ "Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2013". Drug Enforcement Administration (DEA), Department of Justice. 20 June 2014. Archived from the original on 14 May 2017. Retrieved 26 July 2014.
  60. ↑ "Ohio Prisons Director Announces Changes to Ohio's Execution Process". Ohio Department of Rehabilitation and Correction. 13 November 2009. Archived from the original on 15 January 2013. Retrieved 17 January 2014.
  61. ↑ "Arizona execution takes two hours". BBC News. 24 July 2014. Retrieved 24 July 2014.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.